| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CD40 |
| Clinical data | |
| Other names | SGN-40 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6452H9964N1732O1998S42 |
| Molar mass | 145111.33 g·mol−1 |
  (what is this?) (verify) | |
Dacetuzumab (also known as SGN-40 or huS2C6) is a humanized monoclonal antibody[1] being developed for the treatment of CD40-positive cancers like non-Hodgkin's lymphoma[2] and hematological malignancies.[3]
This drug was developed by Seattle Genetics, Inc.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Dacetuzumab, American Medical Association.
- ^ Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, et al. (September 2009). "Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma". Journal of Clinical Oncology. 27 (26): 4371–7. doi:10.1200/JCO.2008.21.3017. PMID 19636010.
- ^ Khubchandani S, Czuczman MS, Hernandez-Ilizaliturri FJ (June 2009). "Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies". Current Opinion in Investigational Drugs. 10 (6): 579–87. PMID 19513947.